RBC Capital Initiates Applied Therapeutics(APLT.US) With Hold Rating, Announces Target Price $12

加皇资本市场首予Applied Therapeutics(APLT.US)持有评级，目标价12美元

moomoo资讯 · 2024/11/29 21:32 · 评级/大行评级

RBC Capital analyst Leonid Timashev initiates coverage on $Applied Therapeutics (APLT.US)$ with a hold rating, and sets the target price at $12.

According to TipRanks data, the analyst has a success rate of 50.6% and a total average return of 17.9% over the past year.

AnalystRecentRatingAutoNews_77373836053936_20241129_884cf99cbc614f1d713f76744d88d630cc5740cc_1732962622017851_mm_en

Furthermore, according to the comprehensive report, the opinions of $Applied Therapeutics (APLT.US)$'s main analysts recently are as follows:

The Complete Response Letter issued by the FDA for govorestat in galactosemia was unexpected and confusing, especially as the FDA seemed unable to overlook the missed primary endpoint when considering full approval. The likelihood of success in galactosemia is now perceived at 50%, following this recent regulatory feedback. Nonetheless, the SORD program, which is assessed separately under accelerated approval by Neurology I, is considered to represent significant value, justifying continued positive sentiment towards the company's prospects.
The FDA's issuance of a complete response letter for govorestat in the treatment of galactosemia was seen as a significant setback, perceived to harm the drug's credibility in a manner difficult to recover from. Details regarding the adverse aspects of the review remain scarce. Expectations have shifted, indicating that forthcoming reviews in similar treatments are likely to be met with increased skepticism by the investment community. Nonetheless, the potential for a commercial opportunity remains robust, with anticipations of a recovery in valuation following potential approval in the coming year.

Note:

TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.

Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.

TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.

加皇资本市场分析师Leonid Timashev首予$Applied Therapeutics (APLT.US)$持有评级，目标价12美元。

根据TipRanks数据显示，该分析师近一年总胜率为50.6%，总平均回报率为17.9%。

AnalystRecentRatingAutoNews_77373836053936_20241129_884cf99cbc614f1d713f76744d88d630cc5740cc_1732962622017851_mm_sc

此外，综合报道，$Applied Therapeutics (APLT.US)$近期主要分析师观点如下：

美国食品和药物管理局针对半乳糖血症的govorestat发布的完整回复信出乎意料且令人困惑，尤其是因为美国食品和药物管理局在考虑全面批准时似乎无法忽视错过的主要终点。根据最近的监管反馈，目前人们认为半乳糖血症成功的可能性为50％。尽管如此，在Neurology I的加速批准下单独评估的SORD计划被认为具有重大价值，这证明了对公司前景的持续乐观情绪。
美国食品药品管理局发布了关于govorestat治疗半乳糖血症的完整回复信，这被视为重大挫折，被认为损害了该药物的可信度，难以恢复。有关审查不利方面的细节仍然很少。预期发生了变化，这表明即将进行的类似疗法审查可能会受到投资界越来越多的怀疑。尽管如此，商业机会的潜力仍然强劲，预计在来年可能获得批准后，估值将回升。

提示:

TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。

TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。

分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。

总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。更多信息

RBC Capital Initiates Applied Therapeutics(APLT.US) With Hold Rating, Announces Target Price $12

RBC Capital Initiates Applied Therapeutics(APLT.US) With Hold Rating, Announces Target Price $12

风险及免责提示

声明